Loading stock data…
ARMP
$7.78+0.21 (+2.77%)
After Hours$7.78+0.00 (+0.00%)· Last close Jun 9
Armata Pharmaceuticals, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Armata Pharmaceuticals, Inc. in the Healthcare sector is trading at $7.78 with a market capitalization of $286M. Wall Street consensus targets $17.50 (2 analysts), implying a +124.9% move over the next 12 months. The stock is currently 52% below its 52-week high of $16.34, remaining 10.2% above its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +124.9% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$7.78
Potential Downside
0%
Whystock Fair Value$7.78
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus2 analysts
Mean target$17.50+124.9%
Range$15.00 – $20.00
Fundamentals
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacte...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$286.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
90.70%
Volume
Today's trading volume
123,814
Recent News
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod
Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks. On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after […]
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?